ARTICLE | Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
March 11, 2023 1:56 AM UTC
Opna Bio has assembled a cancer pipeline of six small molecule therapies, featuring a program against FMRP, a protein best known for its role in fragile X syndrome, as the centerpiece. In addition to leveraging the latest science on the evolving roles of FMRP, the company seized an opportunity to acquire five programs from Plexxikon, former company of co-founder and CEO Gideon Bollag.
Opna Bio S.A. launched Nov. 21, 2022, with a $38 million series A co-led by Longitude Capital and Northpond Ventures, and a license to the FMRP program from co-founder Douglas Hanahan’s lab at the Swiss Federal Institute of Technology Lausanne (EPFL). ...